Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 2
1991 3
1993 1
1996 2
1997 2
1998 1
1999 2
2000 1
2001 3
2002 4
2003 8
2004 2
2005 3
2007 1
2008 1
2009 3
2010 2
2011 5
2012 6
2013 1
2014 6
2016 2
2017 7
2018 2
2019 8
2020 12
2021 11
2022 5
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

106 results

Results by year

Filters applied: . Clear all
Page 1
N6-Methyladenosine Reader YTHDF1 Promotes ARHGEF2 Translation and RhoA Signaling in Colorectal Cancer.
Wang S, Gao S, Zeng Y, Zhu L, Mo Y, Wong CC, Bao Y, Su P, Zhai J, Wang L, Soares F, Xu X, Chen H, Hezaveh K, Ci X, He A, McGaha T, O'Brien C, Rottapel R, Kang W, Wu J, Zheng G, Cai Z, Yu J, He HH. Wang S, et al. Among authors: rottapel r. Gastroenterology. 2022 Apr;162(4):1183-1196. doi: 10.1053/j.gastro.2021.12.269. Epub 2021 Dec 28. Gastroenterology. 2022. PMID: 34968454 Free article.
BACKGROUND & AIMS: N6-methyladenosine (m(6)A) governs the fate of RNAs through m(6)A readers. Colorectal cancer (CRC) exhibits aberrant m(6)A modifications and expression of m(6)A regulators. ...
BACKGROUND & AIMS: N6-methyladenosine (m(6)A) governs the fate of RNAs through m(6)A readers. Colorectal cancer (CRC) exhibits ab …
Gain-of-function variants in SYK cause immune dysregulation and systemic inflammation in humans and mice.
Wang L, Aschenbrenner D, Zeng Z, Cao X, Mayr D, Mehta M, Capitani M, Warner N, Pan J, Wang L, Li Q, Zuo T, Cohen-Kedar S, Lu J, Ardy RC, Mulder DJ, Dissanayake D, Peng K, Huang Z, Li X, Wang Y, Wang X, Li S, Bullers S, Gammage AN, Warnatz K, Schiefer AI, Krivan G, Goda V, Kahr WHA, Lemaire M; Genomics England Research Consortium; Lu CY, Siddiqui I, Surette MG, Kotlarz D, Engelhardt KR, Griffin HR, Rottapel R, Decaluwe H, Laxer RM, Proietti M, Hambleton S, Elcombe S, Guo CH, Grimbacher B, Dotan I, Ng SC, Freeman SA, Snapper SB, Klein C, Boztug K, Huang Y, Li D, Uhlig HH, Muise AM. Wang L, et al. Among authors: rottapel r. Nat Genet. 2021 Apr;53(4):500-510. doi: 10.1038/s41588-021-00803-4. Epub 2021 Mar 29. Nat Genet. 2021. PMID: 33782605 Free PMC article.
Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer.
Marastoni S, Madariaga A, Pesic A, Nair SN, Li ZJ, Shalev Z, Ketela T, Colombo I, Mandilaras V, Cabanero M, Bruce JP, Li X, Garg S, Wang L, Chen EX, Gill S, Dhani NC, Zhang W, Pintilie M, Bowering V, Koritzinsky M, Rottapel R, Wouters BG, Oza AM, Joshua AM, Lheureux S. Marastoni S, et al. Among authors: rottapel r. Cancer Res Commun. 2022 May 4;2(5):293-306. doi: 10.1158/2767-9764.CRC-22-0037. eCollection 2022 May. Cancer Res Commun. 2022. PMID: 36875717 Free PMC article.
We then demonstrated that the combination of itraconazole and chloroquine displayed Bliss defined synergy in EOC cancer cell lines. Furthermore, there was an association of cytotoxic synergy with the ability to induce functional lysosome dysfunction, by chloroquine. ...SIG …
We then demonstrated that the combination of itraconazole and chloroquine displayed Bliss defined synergy in EOC cancer cell lines. F …
E3-ubiquitin ligases and recent progress in osteoimmunology.
Asano Y, Matsumoto Y, Wada J, Rottapel R. Asano Y, et al. Among authors: rottapel r. Front Immunol. 2023 Feb 23;14:1120710. doi: 10.3389/fimmu.2023.1120710. eCollection 2023. Front Immunol. 2023. PMID: 36911671 Free PMC article. Review.
Bone dynamics and inflammation: lessons from rare diseases.
Matsumoto Y, Rottapel R. Matsumoto Y, et al. Among authors: rottapel r. Immunol Med. 2020 Jun;43(2):61-64. doi: 10.1080/25785826.2020.1720104. Epub 2020 Jan 30. Immunol Med. 2020. PMID: 31999934 Review.
Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT).
Genta S, Lajkosz K, Yee NR, Spiliopoulou P, Heirali A, Hansen AR, Siu LL, Saibil S, Stayner LA, Yanekina M, Sauder MB, Keshavarzi S, Salawu A, Vornicova O, Butler MO, Bedard PL, Razak ARA, Rottapel R, Chruscinski A, Coburn B, Spreafico A. Genta S, et al. Among authors: rottapel r. J Exp Clin Cancer Res. 2023 Oct 21;42(1):276. doi: 10.1186/s13046-023-02851-6. J Exp Clin Cancer Res. 2023. PMID: 37865776 Free PMC article.
METHODS: We used custom autoantigen (AutoAg) microarrays to profile AutoAb related to irAEs in patients receiving ICI. Plasma was collected before and after ICI from cancer patients participating in two clinical trials (NCT03686202, NCT02644369). ...
METHODS: We used custom autoantigen (AutoAg) microarrays to profile AutoAb related to irAEs in patients receiving ICI. Plasma was collected …
Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort.
Roberts J, Ennis D, Hudson M, Ye C, Saltman A, Himmel M, Rottapel R, Pope J, Hoa S, Tisseverasinghe A, Fifi-Mah A, Maltez N, Jamal S. Roberts J, et al. Among authors: rottapel r. Autoimmun Rev. 2020 Aug;19(8):102595. doi: 10.1016/j.autrev.2020.102595. Epub 2020 Jun 11. Autoimmun Rev. 2020. PMID: 32535092 Review.
OBJECTIVE: Although immune checkpoint inhibitors (ICI) have revolutionized cancer therapy, their use is associated with immune toxicities referred to as immune-related adverse events (irAE). ...This study can inform the development of evidence-based recommendations to opti …
OBJECTIVE: Although immune checkpoint inhibitors (ICI) have revolutionized cancer therapy, their use is associated with immune toxici …
Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference.
Bast RC Jr, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, Edwards RP, Elias KM, Ennis D, Futreal A, Gershenson DM, Greenberg RA, Huntsman DG, Ji JXY, Kohn EC, Iavarone C, Lengyel ER, Levine DA, Lord CJ, Lu Z, Mills GB, Modugno F, Nelson BH, Odunsi K, Pilsworth JA, Rottapel RK, Powell DJ Jr, Shen L, Shih IM, Spriggs DR, Walton J, Zhang K, Zhang R, Zou L. Bast RC Jr, et al. Among authors: rottapel rk. Cancer. 2019 Jun 15;125(12):1963-1972. doi: 10.1002/cncr.32004. Epub 2019 Mar 5. Cancer. 2019. PMID: 30835824 Free PMC article.
Substantial progress has been made in understanding ovarian cancer at the molecular and cellular level. Significant improvement in 5-year survival has been achieved through cytoreductive surgery, combination platinum-based chemotherapy, and more effective treatment of recu …
Substantial progress has been made in understanding ovarian cancer at the molecular and cellular level. Significant improvement in 5- …
106 results